Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study

NCT04091204 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Interventions

DRUG: Olaparib tablets

Sponsor

National Cancer Institute, Naples